loading
Milestone Pharmaceuticals Inc stock is traded at $1.28, with a volume of 1.43M. It is up +1.59% in the last 24 hours and down -31.91% over the past month. Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.26
Open:
$1.28
24h Volume:
1.43M
Relative Volume:
0.61
Market Cap:
$53.89M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-0.9209
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
+44.00%
1M Performance:
-31.91%
6M Performance:
-11.11%
1Y Performance:
-18.99%
1-Day Range:
Value
$1.21
$1.32
1-Week Range:
Value
$0.88
$1.32
52-Week Range:
Value
$0.6254
$2.75

Milestone Pharmaceuticals Inc Stock (MIST) Company Profile

Name
Name
Milestone Pharmaceuticals Inc
Name
Phone
(514) 336-0444
Name
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Name
Employee
33
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
MIST's Discussions on Twitter

Compare MIST with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MIST
Milestone Pharmaceuticals Inc
1.28 53.89M 0 -59.69M -46.54M -1.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-22-24 Initiated Rodman & Renshaw Buy
Jun-20-23 Downgrade Jefferies Buy → Hold
Apr-22-22 Upgrade Piper Sandler Neutral → Overweight
Mar-05-21 Initiated H.C. Wainwright Buy
Jul-29-20 Upgrade Oppenheimer Perform → Outperform
Jul-24-20 Upgrade Jefferies Hold → Buy
Mar-25-20 Downgrade Jefferies Buy → Hold
Mar-24-20 Downgrade Oppenheimer Outperform → Perform
Mar-24-20 Downgrade Piper Sandler Overweight → Neutral
Jun-04-19 Initiated Oppenheimer Outperform
Jun-03-19 Initiated Cowen Outperform
Jun-03-19 Initiated Jefferies Buy
Jun-03-19 Initiated Piper Jaffray Overweight
View All

Milestone Pharmaceuticals Inc Stock (MIST) Latest News

pulisher
Apr 23, 2025

Milestone Pharmaceuticals Inc (MIST) looking to reclaim success with recent performance - Sete News

Apr 23, 2025
pulisher
Apr 23, 2025

Market Watch Highlights: Milestone Pharmaceuticals Inc (MIST) Ends on an Upturn Note at 1.06 - DWinneX

Apr 23, 2025
pulisher
Apr 22, 2025

Milestone Pharmaceuticals Inc’s Mixed Bag: Down -30.82% in 6 Months, Down -48.21% in 30 Days - investchronicle.com

Apr 22, 2025
pulisher
Apr 22, 2025

A stock that deserves closer examination: Milestone Pharmaceuticals Inc (MIST) - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Milestone Pharmaceuticals Inc [MIST] Investment Guide: What You Need to Know - knoxdaily.com

Apr 22, 2025
pulisher
Apr 09, 2025

Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT - Seeking Alpha

Apr 09, 2025
pulisher
Apr 05, 2025

Research Analysts Set Expectations for MIST Q1 Earnings - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

MIST stock touches 52-week low at $0.7 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

MIST stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Cut to Hold at TD Cowen - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India

Apr 01, 2025
pulisher
Mar 31, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Reta - Asianet Newsable

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone flagging following CRL - The Pharma Letter

Mar 28, 2025
pulisher
Mar 28, 2025

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma says FDA declined to approve heart disorder therapy - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener

Mar 28, 2025
pulisher
Mar 27, 2025

Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews

Mar 27, 2025

Milestone Pharmaceuticals Inc Stock (MIST) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):